Search

Your search keyword '"Rülicke, Thomas"' showing total 800 results

Search Constraints

Start Over You searched for: Author "Rülicke, Thomas" Remove constraint Author: "Rülicke, Thomas"
800 results on '"Rülicke, Thomas"'

Search Results

2. 15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

5. A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia

9. WDFY3 mutation alters laminar position and morphology of cortical neurons

10. Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy

12. Shared behavioural impairments in visual perception and place avoidance across different autism models are driven by periaqueductal grey hypoexcitability in Setd5 haploinsufficient mice

15. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia

16. Skin Barrier Development Depends on CGI-58 Protein Expression during Late-Stage Keratinocyte Differentiation

17. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML

19. Effects of Tulp4 deficiency on murine embryonic development and adult phenotype.

20. A lineage-specificSTAT5BN642Hmouse model to study NK-cell leukemia

21. C-type lectin receptor expression is a hallmark of neutrophils infiltrating the skin in epidermolysis bullosa acquisita

22. Inducible overexpression of a FAM3C/ILEI transgene has pleiotropic effects with shortened life span, liver fibrosis and anemia in mice

23. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia

25. Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives

36. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

37. Large neutral amino acid levels tune perinatal neuronal excitability and survival

38. Supplementary Table 6 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

39. Supplementary Table 7 - 8 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

40. Supplementary Figure 2 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

41. Supplementary Table 5 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

42. Supplementary Figure 3 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

43. Supplementary Tables 1 - 4 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

44. Supplementary Figure 1 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

45. Supplementary Table 9 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

46. Phenotypic characterization of disease‐initiating stem cells in JAK2 ‐ or CALR ‐mutated myeloproliferative neoplasms

Catalog

Books, media, physical & digital resources